Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris

European Heart Journal

Volumn 12, Issue 2, 1991, Pages 157-161

  Jansson, J H ^a   Nilsson, T K ^b   Olofsson, B O ^b  

^a Skelleftea Hospital   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Coronary artery disease; Fibrinolysis; Plasminogen activator inhibitor; Risk factors; Tissue plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; FEMALE; FIBRINOLYSIS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ANGINA PECTORIS; CAUSE OF DEATH; CEREBROVASCULAR DISORDERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; MYOCARDIAL INFARCTION; PLASMINOGEN INACTIVATORS; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0025970133     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.eurheartj.a059862     Document Type: Article

References (24)

1. Hamsten A, Wilman B, De Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
2. Nilsson TK, Johnson O. The extrinsic fibrinolytic system in survivors of myocardial infarction. Thromb Res 1987; 48: 621-30.
3. Olofsson B-O, Dahlén G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77-82.
4. Aznar J, Estelle's A, Tormo G et al. Plasminogen activator inhibitor and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59: 535-41.
5. Francis RB, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988; 115: 776-80.
6. Hamsten A, Walldius G, Blombäck M et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-8.
7. Nomenclature and criteria for diagnosis of ishemic heart disease; report of the Joint International Society and Federation of Cardiology/World Health Organisation Task Force on Standardization of Clinical Nomenclature. Circulation 1979; 59: 607-9.
8. Ray AA. SAS User's Guide: Basics. Cary, NC, SAS Institute, 1986.
9. Cox DR. Regression models and life tables (with discussion) J R Stat Soc 1972; 34: 187-220.
10. Sherman CT, Litvack F, Grundfest W et al., Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986; 315: 913-9.
11. de Wood MA, Spores J, Notske R, Mouser LT, Burroughs R. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
12. Davies MJ, Thomas A. Thombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137-40.
13. Meade TW, Brozovic M, Chakrabarti R. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart study. Lancet 1986; i: 533-7.
14. Vanderkerckhove Y, Baele G, de Puydt H, Weyne A, Clement D. Plasma tissue plasminogen activator levels in patients with coronary heart disease. Thromb Res 1988; 50: 449-53.
15. Oseroff A, Krishnamurti C, Hassett A, Tang D, Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 1989; 113: 88-93.
16. Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1979; i: 153-6.
17. Sundell B, Nilsson T, Nygren C, Hallmans G. The extrinsic fibrinolytic system in relation to body build, nutritional and endocrine factors in healthy young women. Scand J Clin Lab Invest 1988; 48: 557-64.
18. Sundell B, Dahlgren S, Rånby M, Lundin E, Stenling R, Nilsson TK. Reduction of elevated plasminogen activator inhi-bitor levels during modest weight loss. Fibrinolysis 1989; 3: 51-3.
19. Jansson JH, Norberg B, Nilsson TK. Impact of acute phase on concentrations of tissue plasminogen activator and plasminogen activator inhibitor in plasma after deep-vein thrombosis or open-heart surgery. Clin Chem 1989; 35: 1544-50.
20. Carlsson LA, Åberg H. Serum triglycerides- an independent risk factor for myocardial infarction but not for angina pectoris. N Engl J Med 1985; 312: 1127.
21. Carlsson LA, Böttiger LE, Åhfeldt PE. Risk factors for myocardial infarction in the Stockholm prospective study - A 14 year follow-up focusing on the role of plasma triglyceride and cholesterol. Acta Med Scand 1979; 206: 351-60.
22. Cambien F, Jacqueson A, Richard JL, Warnet JM, Ducimetière P, Claude JR. Is the level of serum triglyceride a significant predictor of coronary death in normocholestererolemic subjects? Am J Epidemiol 1987; 126: 86-93.
23. Simpson HCR, Meade TW, Stirling Y, Mann JI, Chakrabarti R, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; i: 786-90.
24. Elkeles RS, Chakrabarti R, Vickers M, Stirling Y, Meade TW. Effect of treatment of hyperlipidemia on haemostatic variables. Br Med J 1980; 281: 973-4.